Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance

Drug Safety

Volumn 29, Issue 9, 2006, Pages 735-768

  Sirot, Eveline Jaquenoud ^a   Van Der Velden, Jan Willem ^b,c   Rentsch, Katharina ^d   Eap, Chin B ^e   Baumann, Pierre ^e  

^a MediQ   (Switzerland)

^b Global Safety and Pharmacovigilance   (Switzerland)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; ATORVASTATIN; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOMIPRAMINE; CLOZAPINE; FELODIPINE; FLUOXETINE; FLUPENTIXOL; FLUVOXAMINE; HALOPERIDOL; KETOCONAZOLE; MEVINOLIN; NEUROLEPTIC AGENT; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; OPIATE; PENICILLIN G; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; TERFENADINE; THIORIDAZINE; TRAMADOL; UNINDEXED DRUG; VENLAFAXINE;

AGITATION; ALGORITHM; AMNESIA; ATAXIA; BONE MARROW TOXICITY; BRONCHOSPASM; CARDIOTOXICITY; CIGARETTE SMOKING; CLINICAL TRIAL; COMA; COMORBIDITY; CONSTIPATION; DELIRIUM; DEPRESSION; DEPRESSIVE PSYCHOSIS; DISORIENTATION; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG INTOXICATION; DRUG METABOLISM; DRUG MONITORING; DRUG OVERDOSE; DRUG SURVEILLANCE PROGRAM; ENVIRONMENTAL FACTOR; FLUSHING; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; GENETIC POLYMORPHISM; GRAND MAL EPILEPSY; HAIR LOSS; HEART ARRHYTHMIA; HEART DISEASE; HEMOLYTIC ANEMIA; HUMAN; HYPERSENSITIVITY; HYPOTENSION; LIFESTYLE; LIVER DYSFUNCTION; LIVER TOXICITY; LUPUS LIKE SYNDROME; NEPHROTOXICITY; PHARMACOGENETICS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; RHABDOMYOLYSIS; SCHIZOPHRENIA; SEDATION; SEIZURE; SEROTONIN SYNDROME; SIDE EFFECT; SLURRED SPEECH; SWEATING; TACHYCARDIA; TINNITUS; TORSADE DES POINTES; TREATMENT RESPONSE; TREMOR; URTICARIA; VAGINA DISEASE; VASODILATATION; WEIGHT GAIN;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ALGORITHMS; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS;

EID: 33748474635     PISSN: 01145916     EISSN: 01145916     Source Type: Journal    
DOI: 10.2165/00002018-200629090-00001     Document Type: Review

References (348)

1. Alexanderson B, Evans DA, Sjoqvist F. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. BMJ 1969; 4 (686): 764-8
2. Alexanderson B. Prediction of steady-state plasma levels of nortriptyline from single oral dose kinetics: a study in twins. Eur J Clin Pharmacol 1973; 6 (1): 44-53
3. Mahgoub A, Idle JR, Dring LG, et al. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; II (8038): 584-6
4. Bertilsson L, Mellstrom B, Sjoqvist F, et al. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet 1981; I (8219): 560-1
5. Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 2001; 250 (3): 186-200
6. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356 (9242): 1667-71
7. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352 (21): 2211-21
8. Classen DC, Pestotnik SL, Evans RS, et al. Computerized surveillance of adverse drug events in hospital patients. JAMA 1991; 266 (20): 2847-51
9. von Euler M, Eliasson E, Ohlen G, et al. Adverse drug reactions causing hospitalization can be monitored from computerized medical records and thereby indicate the quality of drug utilization. Pharmacoepidemiol Drug Saf 2006; 15 (3): 179-84
10. Green CF, Mottram DR, Rowe PH, et al. Adverse drug reactions as a cause of admission to an acute medical assessment unit: a pilot study. J Clin Pharm Ther 2000; 25 (5): 355-61
11. Lapeyre-Mestre M, Gary J, Machelard-Roumagnac M, et al. Incidence and cost of adverse drug reactions in a French cancer institute. Eur J Clin Pharmacol 1997; 53 (1): 19-22
12. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279 (15): 1200-5
13. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329 (7456): 15-9
14. Dormann H, Criegee-Rieck M, Neubert A, et al. Lack of awareness of community-acquired adverse drug reactions upon hospital admission: dimensions and consequences of a dilemma. Drug Saf 2003; 26 (5): 353-62
15. Queneau P, Bannwarth B, Carpentier F, et al. Adverse drug effects observed at French admissions departments and emergency services (Prospective study of the National Educational Association for Teaching Therapeutics and proposals for preventive measures [in French]. Bull Acad Natl Med 2003; 187 (4): 647-66
16. Johnson JA, Bootman JL. Drug-related morbidity and mortality: a cost-of-illness model. Arch Intern Med 1995; 155 (18): 1949-56
17. Lepori V, Perren A, Marone C. Adverse internal medicine drug effects at hospital admission [in German]. Schweiz Med Wochenschr 1999; 129 (24): 915-22
18. Schneeweiss S, Hasford J, Gottler M, et al. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol 2002; 58 (4): 285-91
19. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002; 36 (9): 1331-6
20. Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277 (4): 301-6
21. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 1997; 277 (4): 307-11
22. Ozdemir V, Shear NH, Kalow W. What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects? Drug Saf 2001; 24 (2): 75-85
23. Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001; 286 (18): 2270-9
24. Guidance for Industry Pharmacogenomic Data Submissions [online]. Available from URL: http://www.fda.gov/cder/guidance/6400fnl.htm [Accessed 2006 Aug 9]
25. Mancama D, Arranz MJ, Kerwin RW. Genetic predictors of therapeutic response to clozapine: current status of research. CNS Drugs 2002; 16 (5): 317-24
26. Van der Weide J, Steijns LS, van Weelden MJ. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 2003; 13 (3): 169-72
27. Eap CB, Bender S, Sirot EJ, et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol 2004; 24 (2): 214-9
28. Mancama D, Kerwin RW. Role of pharmacogenomics in individualising treatment with SSRIs. CNS Drugs 2003; 17 (3): 143-51
29. Lerer B, Macciardi F. Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions. Int J Neuropsychopharmacol 2002; 5 (3): 255-75
30. Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104 (3): 173-92
31. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9 (5): 442-73
32. Campbell TJ, Williams KM. Therapeutic drug monitoring: antiarrhythmic drugs. Br J Clin Pharmacol 2001; 52 Suppl. 1: 21S-34S
33. Girard T. Pharmakogenetik in der Anästhesie. Schweiz Med Forum 2004; 4: 1199-202
34. Lennard L. Therapeutic drug monitoring of antimetabolic cytotoxic drugs. Br J Clin Pharmacol 1999; 47 (2): 131-43
35. Lennard L. Therapeutic drug monitoring of cytotoxic drugs. Br J Clin Pharmacol 2001; 52 Suppl. 1: 75S-87S
36. Raetz Bravo AE, Tchambaz L, Kraehenbuehl-Melcher A, et al. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf 2005; 28 (3): 263-75
37. Starling RC, Hare JM, Hauptman P, et al. Therapeutic drug monitoring for everolismus in heart transplant recipients based on exposure-effect modeling. Am J Transplant 2004; 4 (12): 2126-31
38. Min DI, Perry PJ, Chen HY, et al. Cyclosporine trough concentrations in predicting allograft rejection and renal toxicity up to 12 months after renal transplantation. Pharmacotherapy 1998; 18 (2): 282-7
39. Eadie MJ. The role of therapeutic drug monitoring in improving the cost effectiveness of anticonvulsant therapy. Clin Pharmacokinet 1995; 29 (1): 29-35
40. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356 (9237): 1255-9
41. Brown CS, Farmer RG, Soberman JE, et al. Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs. Clin Pharmacokinet 2004; 43 (1): 33-56
42. Mjorndal T, Boman MD, Hagg S, et al. Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiol Drug Saf 2002; 11 (1): 65-72
43. Jaquenoud Sirot E, Eap CB, Baumann P. Bedeutung von TDM und Pharmakogenetik bei Untersuchungen über Arzneimittelsicherheit in der Psychiatrie. Psychopharmakotherapie 2003; 10 (1): 5-10
44. Jaquenoud Sirot E, Zullino D. Guide to combination therapy in psychiatry with special emphasis on fluvoxamine. Hannover: Hannoversche Ärzte-Verlags-Union, Hannover, 2000
45. Poolsup N, Li Wan PA, Knight TL. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther 2000; 25 (3): 197-220
46. Ng CH, Schweitzer I, Norman T, et al. The emerging role of pharmacogenetics: implications for clinical psychiatry. Aust N Z J Psychiatry 2004; 38 (7): 483-9
47. Coutts RT, Urichuk LJ. Polymorphic cytochromes P450 and drugs used in psychiatry. Cell Mol Neurobiol 1999; 19 (3): 325-54
48. Murray M. P450 enzymes: inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet 1992; 23 (2): 132-46
49. Guengerich FP, Wu ZL, Bartleson CJ. Function of human cytochrome P450s: characterization of the orphans. Biochem Biophys Res Commun 2005; 338 (1): 465-9
50. Guengerich FP. Role of cytochrome P450 enzymes in drug-drug interactions. Adv Pharmacol 1997; 43: 7-35
51. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15 (1): 1-5
52. Crettol S, Deglon JJ, Besson J, et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 2005; 78 (6): 593-604
53. Hesse LM, Venkatakrishnan K, Court MH, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 2000; 28 (10): 1176-83
54. Roh HK, Chung JY, Oh DY, et al. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol 2001; 52 (3): 265-71
55. Baumann P, Zullino DF, Eap CB. Enantiomers' potential in psychopharmacology: a critical analysis with special emphasis on the antidepressant escitalopram. Eur Neuropsychopharmacol 2002; 12 (5): 433-44
56. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286 (5439): 487-91
57. Vogel F. Moderne probleme der humangenetik. Ergebn Inn Med Kinderheilk 1959; 12: 52-125
58. Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 2001; 22 (6): 298-305
59. Sutrop M. Pharmacogenetics: ethical issues. Bioethics 2004; 18 (4): iii-viii
60. Weber WW. Pharmacogenetics. 1st ed. New York: Oxford University Press, 1997
61. Bertilsson L, Aberg-Wistedt A, Gustafsson LL, et al. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 1985; 7 (4): 478-80
62. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348 (6): 529-37
63. Meisel C, Gerloff T, Kirchheiner J, et al. Implications of pharmacogenetics for individualizing drug treatment and for study design. J Mol Med 2003; 81 (3): 154-67
64. Lerer B. Pharmacogenetics of psychotropic drugs. New York: Cambridge University Press, 2002
65. Lindpainter K. Pharmacogenetics and the future of medical practice. J Mol Med 2003; 81: 141-53
66. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 2003; 348 (6): 538-49
67. Lundqvist E, Johansson I, Ingelman-Sundberg M. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 1999; 226 (2): 327-38
68. Dalen P, Dahl ML, Ruiz ML, et al. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998; 63 (4): 444-52
69. Lovlie R, Daly AK, Matre GE, et al. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics 2001; 11 (1): 45-55
70. Bergmann TK, Bathum L, Brosen K. Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6. Eur J Clin Pharmacol 2001; 57 (2): 123-7
71. Xie HG, Kim RB, Wood AJ, et al. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41: 815-50
72. Pi EH, Simpson GM. Cross-cultural psychopharmacology: a current clinical perspective. Psychiatr Serv 2005; 56 (1): 31-3
73. Burroughs VJ, Maxey RW, Levy RA. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J Natl Med Assoc 2002; 94 (10 Suppl.): 1-26
74. Ng CH, Chong SA, Lambert T, et al. An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. Int Clin Psychopharmacol 2005; 20 (3): 163-8
75. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270 (1): 414-23
76. Linnet K, Olesen OV. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. Drug Metab Dispos 1997; 25 (12): 1379-82
77. Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997; 7 (1): 59-64
78. Matsuda KT, Cho MC, Lin KM, et al. Clozapine dosage, serum levels, efficacy, and side-effect profiles: a comparison of Korean-American and Caucasian patients. Psychopharmacol Bull 1996; 32: 253-7
79. Nakajima M, Yokoi T, Mizutani M, et al. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem (Tokyo) 1999; 125 (4): 803-8
80. Allorge D, Chevalier D, Lo-Guidice JM, et al. Identification of a novel splice-site mutation in the CYP1A2 gene. Br J Clin Pharmacol 2003; 56 (3): 341-4
81. Aklillu E, Carrillo JA, Makonnen E, et al. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol 2003; 64 (3): 659-69
82. Sachse C, Brockmöller J, Bauer S, et al. Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999; 47 (4): 445-9
83. Han XM, Ou-Yang DS, Lu PX, et al. Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2. Pharmacogenetics 2001; 11 (5): 429-35
84. Aynacioglu AS, Brockmöller J, Bauer S, et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999; 48 (3): 409-15
85. Garcia-Martin E, Martinez C, Ladero JM, et al. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. Eur J Clin Pharmacol 2001; 57 (1): 47-9
86. Scordo MG, Caputi AP, D'Arrigo C, et al. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004; 50 (2): 195-200
87. Wang SL, Huang J, Lai MD, et al. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995; 5 (1): 37-42
88. Kimura M, Ieiri I, Mamiya K, et al. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit 1998; 20 (3): 243-7
89. Scordo MG, Aklillu E, Yasar U, et al. Genetic polymorphism of cytochrome P4502C9 in a Caucasian and a black African population. Br J Clin Pharmacol 2001; 52 (4): 447-50
90. Gaedigk A. Interethnic differences of drug-metabolizing enzymes. Int J Clin Pharmacol Ther 2000; 38 (2): 61-8
91. Dandara C, Masimirembwa CM, Magimba A, et al. Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients. Eur J Clin Pharmacol 2001; 57 (1): 11-7
92. Evans DA, Krahn P, Narayanan N. The mephenytoin (cytochrome P4502C19). and dextromethorphan (cytochrome P4502D6). polymorphisms in Saudi Arabians and Filipinos. Pharmacogenetics 1995; 5 (2): 64-71
93. Aynacioglu AS, Sachse C, Bozkurt A, et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther 1999; 66 (2): 185-92
94. Roh HK, Dahl ML, Johansson I, et al. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 1996; 6 (5): 441-7
95. Roh HK, Dahl ML, Tybring G, et al. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 1996; 6 (6): 547-51
96. Itoh K, Inoue K, Yanagiwara S, et al. A rapid and simple detection of genetic defects responsible for the phenotypic polymorphism of cytochrome P4502C19. Biol Pharm Bull 1999; 22 (1): 77-9
97. Kimura M, Ieiri I, Mamiya K, et al. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit 1998; 20 (3): 243-7
98. Sachse C, Brockmöller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60 (2): 284-95
99. Dahl AA, Lowert A, Asserson S, et al. Hydroxylation polymorphism of debrisoquine hydroxylase (CYP2D6) in patients with schizophrenia in Norway and Denmark. Hum Psychopharmacol Clin Exp 1998; 13: 509-11
100. Tefre T, Daly AK, Armstrong M, et al. Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. Pharmacogenetics 1994; 4 (2): 47-57
101. Madsen H, Nielsen KK, Brosen K. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms: a population study. Br J Clin Pharmacol 1995; 39 (4): 433-9
102. Agundez JA, Ledesma MC, Ladero JM, et al. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995; 57 (3): 265-9
103. McLellan RA, Oscarson M, Seidegard J, et al. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997; 7 (3): 187-91
104. Ji L, Pan S, Wu J, et al. Genetic polymorphisms of CYP2D6 in Chinese mainland. Chin Med J (Engl) 2002; 115 (12): 1780-4
105. Bradford LD, Gaedigk A, Leeder JS. High frequency of CYP2D6 poor and "intermediate" metabolizers in black populations: a review and preliminary data. Psychopharmacol Bull 1998; 34 (4): 797-804
106. Bradford LD, Kirlin WG. Polymorphism of CYP2D6 in Black populations: implications for psychopharmacology. Int J Neuropsychopharmcol 1998; 1 (2): 173-85
107. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002; 3 (2): 229-43
108. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27 (4): 383-91
109. Saeki M, Saito Y, Nakamura T, et al. Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Hum Mutat 2003; 21 (6): 653
110. Chou FC, Tzeng SJ, Huang JD. Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab Dispos 2001; 29 (9): 1205-9
111. Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 2001; 299 (3): 825-31
112. Bertilsson L, Lou YQ, Du YL, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992; 51 (4): 388-97
113. Fukuda T, Yamamoto I, Nishida Y, et al. Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol 1999; 47 (4): 450-3
114. Bertilsson L, Dahl ML, Dalen P, et al. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002; 53 (2): 111-22
115. Bertilsson L, Dahl ML, Tybring G. Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand Suppl 1997; 391: 14-21
116. Kirchheiner J, Bertilsson L, Bruus H, et al. Individualized medicine: implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders. Pharmacopsychiatry 2003; 36 Suppl. 3: S235-43
117. Kirchheiner J, Fuhr U, Brockmöller J. Pharmacogenetics-based therapeutic recommendations: ready for clinical practice? Nat Rev Drug Discov 2005; 4 (8): 639-47
118. Lessard E, Yessine MA, Hamelin BA, et al. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 1999; 9 (4): 435-43
119. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004; 351 (27): 2827-31
120. Dalen P, Frengell C, Dahl ML, et al. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit 1997; 19 (5): 543-4
121. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37 (6): 243-65
122. Stephan PL, Jaquenoud Sirot E, Mueller B, et al. Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP 3A4/5 activity: a pharmacovigilance case report. Pharmacopsychiatry 2006; 39 (4): 150-2
123. Furuta T, Shirai N, Xiao F, et al. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 2001; 70 (5): 484-92
124. Furuta T, Ohashi K, Kosuge K, et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999; 65 (5): 552-61
125. Furuta T, Takashima M, Shirai N, et al. Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient. Clin Pharmacol Ther 2000; 67 (6): 684-9
126. Furuta T, Shirai N, Takashima M, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001; 69 (3): 158-68
127. Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129 (12): 1027-30
128. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287 (13): 1690-8
129. Scordo MG, Pengo V, Spina E, et al. Influence of CYP2C9 and SCYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002; 72 (6): 702-10
130. Hillman MA, Wilke RA, Yale SH, et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res 2005; 3 (3): 137-45
131. Özdemir V, Kalow W, Posner P, et al. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patients with schizophrenia. J Clin Psychopharmacol 2001; 21 (4): 398-407
132. Eap CB, Buclin T, Hustert E, et al. Pharmacokinetics of midazolam in CYP3A4 and CYP3A5 genotyped subjects. Eur J Clin Pharmacol 2004; 60 (4): 231-6
133. Shah RR. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Drug Saf 2004; 27 (3): 145-72
134. Brandolese R, Scordo MG, Spina E, et al. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin Pharmacol Ther 2001; 70 (4): 391-4
135. Kidd RS, Curry TB, Gallagher S, et al. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 2001; 11 (9): 803-8
136. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353 (9154): 717-9
137. Kidd RS, Straughn AB, Meyer MC, et al. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 1999; 9 (1): 71-80
138. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45 (6): 525-38
139. Kapitany T, Meszaros K, Lenzinger E, et al. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res 1998; 32 (2): 101-6
140. Brosen K. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther Drug Monit 1996; 18 (4): 393-6
141. Dahl ML, Sjoqvist F. Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics. Ther Drug Monit 2000; 22 (1): 114-7
142. DeVane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry 1994; 55 Suppl.: 38-45
143. Otani K, Aoshima T. Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit 2000; 22 (1): 118-21
144. Steimer W, Potter JM. Pharmacogenetic screening and therapeutic drugs. Clin Chim Acta 2002; 315 (1-2): 137-55
145. Wilke RA, Reif DM, Moore JH. Combinatorial pharmacogenetics. Nat Rev Drug Discov 2005; 4 (11): 911-8
146. Lange-Asschenfeldt C, Weigmann H, Hiemke C, et al. Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology. J Clin Psychopharmacol 2002; 22 (4): 440-1
147. Mahlberg R, Kunz D, Sasse J, et al. Serotonin syndrome with tramadol and citalopram (letter). Am J Psychiatry 2004; 161 (6): 1129
148. Kesavan S, Sobala GM. Serotonin syndrome with fluoxetine plus tramadol. J R Soc Med 1999; 92 (9): 474-5
149. Lin JH, Yamazaki M. Clinical relevance of P-glycoprotein in drug therapy. Drug Metab Rev 2003; 35 (4): 417-54
150. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003; 42 (1): 59-98
151. Levy RH. Metabolic drug interactions. Philadelphia: Lippincott Williams & Wilkins, 2005
152. Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998; 35 (5): 361-90
153. Olesen OV, Linnet K. Fluvoxamine-clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. J Clin Psychopharmacol 2000; 20 (1): 35-42
154. Fang J, Coutts RT, McKenna KF, et al. Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch Pharmacol 1998; 358 (5): 592-9
155. Eiermann B, Engel G, Johansson I, et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997; 44: 439-46
156. Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 2005; 4 (10): 825-33
157. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32 (3): 210-58
158. Bonnabry P, Sievering J, Leemann T, et al. Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studies. Clin Pharmacokinet 2001; 40 (9): 631-40
159. Lin JH, Lu AY. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 2001; 41: 535-67
160. Schmider J, Von Moltke LL, Shader RI, et al. Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine. Drug Metab Rev 1999; 31 (2): 545-60
161. Obach RS, Walsky RL, Venkatakrishnan K, et al. In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 2005; 78 (6): 582-92
162. Obach RS, Walsky RL, Venkatakrishnan K, et al. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 2006; 316 (1): 336-48
163. Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 1997; 17 (3): 208-21
164. Morales N, Vermette H. Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine. Psychosomatics 2005; 46 (3): 274-5
165. Bhatara VS, Magnus RD, Paul KL, et al. Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Ann Pharmacother 1998; 32 (4): 432-6
166. Coplan JD, Gorman JM. Detectable levels of fluoxetine metabolites after discontinuation: an unexpected serotonin syndrome. Am J Psychiatry 1993; 150 (5): 837
167. Ciraulo DA, Shader RI, Greenblatt DJ, et al. Basic concepts. In: Ciraulo DA, Shader RI, Greenblatt DJ, et al., editors. Drug interactions in psychiatry. Maryland, USA: Williams & Wilkins, 1995: 1-28
168. Saito M, Yasui-Furukori N, Nakagami T, et al. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. J Clin Psychopharmacol 2005; 25 (6): 527-32
169. Paus E, Jonzier-Perey M, Cochard N, et al. Chirality in the new generation of antidepressants: stereoselective analysis of the enantiomers of mirtazapine, N-demethylmirtazapine, and 8-hydroxymirtazapine by LC-MS. Ther Drug Monit 2004; 26 (4): 366-74
170. Bondolfi G, Chautems C, Rochat B, et al. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology (Berl) 1996; 128 (4): 421-5
171. Bondolfi G, Lissner C, Kosel M, et al. Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. Int J Neuropsychopharmacol 2000; 3 (1): 55-60
172. Eap CB, Bertel-Laubscher R, Zullino D, et al. Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report. Pharmacopsychiatry 2000; 33 (3): 112-5
173. Steinacher L, Vandel P, Zullino DF, et al. Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. Eur Neuropsychopharmacol 2002; 12 (3): 255-60
174. Gibaldi M. Stereoselective and isozyme-selective drug interactions. Chirality 1993; 5 (6): 407-13
175. Gidal BE, Sorkness CA, McGill KA, et al. Evaluation of a potential enantioselective interaction between ticlopidine and warfarin in chronically anticoagulated patients. Ther Drug Monit 1995; 17 (1): 33-8
176. Ciusani E, Zullino DF, Eap CB, et al. Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. J Psychopharmacol 2004; 18 (4): 559-66
177. Zhou Q, Chan E. Effect of omeprazole on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats. Eur J Pharm Sci 2003; 20 (4-5): 439-49
178. Andersson T, Hassan-Alin M, Hasselgren G, et al. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 40 (7): 523-37
179. Knezevic B, Ramseier F, Jaquenoud Sirot E. Clozapine-fluvoxamine combination therapy: how much fluvoxamine? Results from a case series. Eur Psychiatry 2006; 21: S225
180. Armstrong SC, Stephans JR. Blood clozapine levels elevated by fluvoxamine: potential for side effects and lower clozapine dosage. J Clin Psychiatry 1997; 58 (11): 499
181. Lu ML, Lane HY, Lin SK, et al. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 2004; 65 (6): 766-71
182. Silver H, Kaplan A, Jahjah N. Fluvoxamine augmentation for clozapine-resistant schizophrenia. Am J Psychiatry 1995; 152 (7): 1098
183. Szegedi A, Anghelescu I, Wiesner J, et al. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 1999; 32 (4): 148-53
184. Wetzel H, Anghelescu I, Szegedi A, et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 1998; 18 (1): 2-9
185. Silver H. Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev 2001; 7 (3): 283-304
186. Fabrazzo M, La Pia S, Monteleone P, et al. Fluvoxamine increases plasma and urinary levels of clozapine and its major metabolites in a time- and dose-dependent manner. J Clin Psychopharmacol 2000; 20 (6): 708-10
187. Christensen M, Tybring G, Mihara K, et al. Low daily 10mg and 20mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther 2002; 71 (3): 141-52
188. Clarke SM, Mulcahy FM, Tjia J, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol 2001; 51 (3): 213-7
189. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 2002; 41 (14): 1153-1193
190. Marzolini C, Troillet N, Telenti A, et al. Efavirenz decreases methadone blood concentrations. AIDS 2000; 14 (9): 1291-2
191. Clarke SM, Mulcahy FM, Tjia J, et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Dis 2001; 33 (9): 1595-7
192. Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 2004; 76 (2): 178-84
193. Cozza KL, Armstrong SC, Oesterheld JR. Concise guide to drug interaction principles for medical practice. 2nd ed. Arlington (VA): American Psychiatric Publishing, Inc., 2003
194. Yue QY, Tomson T, Sawe J. Carbamazepine and cigarette smoking induce differentially the metabolism of codeine in man. Pharmacogenetics 1994; 4 (4): 193-8
195. Bondolfi G, Morel F, Crettol S, et al. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit 2005; 27 (4): 539-43
196. de Leon J. Atypical antipsychotic dosing: the effect of smoking and caffeine. Psychiatr Serv 2004; 55 (5): 491-3
197. Zullino DF, Delessert D, Eap CB, et al. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol 2002; 17 (3): 141-3
198. Carrillo JA, Herraiz AG, Ramos SI, et al. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 2003; 23 (2): 119-27
199. Saito M, Hirata-Koizumi M, Matsumoto M, et al. Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies. Drug Saf 2005; 28 (8): 677-94
200. Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 2004; 4 (5): 281-97
201. Dahan A, Altman H. Food-drug interaction: grapefruit juice augments drug bioavailability: mechanism, extent and relevance. Eur J Clin Nutr 2004; 58 (1): 1-9
202. Martin J, Krum H. Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant? Drug Saf 2003; 26 (1): 13-21
203. Harris RZ, Jang GR, Tsunoda S. Dietary effects on drug metabolism and transport. Clin Pharmacokinet 2003; 42 (13): 1071-88
204. Mills E, Wu P, Johnston BC, et al. Natural health product-drug interactions: a systematic review of clinical trials. Ther Drug Monit 2005; 27 (5): 549-57
205. Carrillo JA, Herraiz AG, Ramos SI, et al. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J Clin Psychopharmacol 1998; 18 (4): 311-6
206. Raaska K, Raitasuo V, Laitila J, et al. Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalised patients. Basic Clin Pharmacol Toxicol 2004; 94 (1): 13-8
207. Ferrari AR, Guerrini R, Gatti G, et al. Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. Ther Drug Monit 2003; 25 (6): 700-8
208. Gatti G, Ferrari AR, Guerrini R, et al. Plasma gabapentin concentrations in children with epilepsy: influence of age, relationship with dosage, and preliminary observations on correlation with clinical response. Ther Drug Monit 2003; 25 (1): 54-60
209. Pollock BG. The pharmacokinetic imperative in late-life depression. J Clin Psychopharmacol 2005; 25 (4 Suppl. 1): S19-23
210. Cotreau MM, Von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 2005; 44 (1): 33-60
211. Byerly MJ, Weber MT, Brooks DL, et al. Antipsychotic medications and the elderly: effects on cognition and implications for use. Drugs Aging 2001; 18 (1): 45-61
212. Barbui C, Nose M, Bindman J, et al. Sex differences in the subjective tolerability of antipsychotic drugs. J Clin Psychopharmacol 2005; 25 (6): 521-6
213. Clark R. Sex differences in antiretroviral therapy-associated intolerance and adverse events. Drug Saf 2005; 28 (12): 1075-83
214. Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry 2004; 161 (8): 1324-33
215. Rademaker M. Do women have more adverse drug reactions? Am J Clin Dermatol 2001; 2 (6): 349-51
216. Jaquenoud Sirot E, Eap CBBP. Follow-up study using TDM and pharmacogenetic testing as tools in pharmacovigilance [abstract]. Drug Saf 2004; 27 (12): 937
217. Pollock BG. Gender differences in psychotropic drug metabolism. Psychopharmacol Bull 1997; 33 (2): 235-41
218. Perry PJ, Bever KA, Arndt S, et al. Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. Biol Psychiatry 1998; 44 (8): 733-8
219. Lane HY, Chang YC, Chang WH, et al. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry 1999; 60 (1): 36-40
220. Weiss U, Marksteiner J, Kemmler G, et al. Effects of age and sex on olanzapine plasma concentrations. J Clin Psychopharmacol 2005; 25 (6): 570-4
221. Beierle I, Meibohm B, Derendorf H. Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 1999; 37 (11): 529-47
222. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet 2002; 41 (5): 329-42
223. Hagg S, Spigset O, Dahlqvist R. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 2001; 51 (2): 169-73
224. Hutson WR, Roehrkasse RL, Wald A. Influence of gender and menopause on gastric emptying and motility. Gastroenterology 1989; 96 (1): 11-7
225. Haack MJ, Bak ML, Beurskens R, et al. Toxic rise of clozapine plasma concentrations in relation to inflammation. Eur Neuropsychopharmacol 2003; 13 (5): 381-5
226. Raaska K, Raitasuo V, Arstila M, et al. Bacterial pneumonia can increase serum concentration of clozapine. Eur J Clin Pharmacol 2002; 58 (5): 321-2
227. Bleau AM, Maurel P, Pichette V, et al. Interleukin-1beta, interleukin-6, tumour necrosis factor-alpha and interferon-gamma released by a viral infection and an aseptic inflammation reduce CYP1A1, 1A2 and 3A6 expression in rabbit hepatocytes. Eur J Pharmacol 2003; 473 (2-3): 197-206
228. Crawford JH, Yang S, Zhou M, et al. Down-regulation of hepatic CYP1A2 plays an important role in inflammatory responses in sepsis. Crit Care Med 2004; 32 (2): 502-8
229. Aitken AE, Richardson TA, Morgan ET. Regulation of drug metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 2006; 46: 123-49
230. Richardson TA, Morgan ET. Hepatic cytochrome P450 gene regulation during endotoxin-induced inflammation in nuclear receptor knockout mice. J Pharmacol Exp Ther 2005; 314 (2): 703-9
231. Wolkenstein P, Loriot MA, Aractingi S, et al. Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS. Pharmacogenetics 2000; 10 (9): 821-8
232. Meisel P. Arylamine N-acetyltransferases and drug response. Pharmacogenomics 2002; 3 (3): 349-66
233. Wormhoudt LW, Commandeur JN, Vermeulen NP. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Crit Rev Toxicol 1999; 29 (1): 59-124
234. Liston HL, Markowitz JS, DeVane CL. Drug glucuronidation in clinical psychopharmacology. J Clin Psychopharmacol 2001; 21 (5): 500-15
235. Hayes JD, Strange RC. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 2000; 61: 154-66
236. Dorne JLCM, Walton K, Renwick AG. Polymorphic CYP2C19 and N-acetylation: human variability in kinetics and pathway-related uncertainty factors. Food Chem Toxicol 2003; 41 (2): 225-45
237. de Leon J. Glucuronidation enzymes, genes and psychiatry. Int J Neuropsychopharmacol 2003; 6: 57-72
238. Burchell B. Genetic variation of human UDP-glucuronosyl-transferase: implications in disease and drug glucuronidation. Am J Pharmacogenomics 2003; 3 (1): 37-52
239. Miners JO, McKinnon RA, Mackenzie PI. Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology 2002; 181-2: 453-6
240. Burchell B, Hume R. Molecular genetic basis of Gilbert's syndrome. J Gastroenterol Hepatol 1999; 14 (10): 960-6
241. Premawardhena A, Fisher CA, Liu YT, et al. The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications. Blood Cells Mol Dis 2003; 31 (1): 98-101
242. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 1998; 95 (14): 8170-4
243. Iyer L, Ratain MJ. Pharmacogenetics and cancer chemotherapy. Eur J Cancer 1998; 34 (10): 1493-9
244. Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11): role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101 (4): 847-54
245. Strolin BM, Ruty B, Baltes E. Induction of endogenous pathways by antiepileptics and clinical implications. Fundam Clin Pharmacol 2005; 19 (5): 511-29
246. Anderson GD, Yau MK, Gidal BE, et al. Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther 1996; 60 (2): 145-56
247. Page RL, O'Neil MG, Yarbrough DR, et al. Fatal toxic epidermal necrolysis related to lamotrigine administration. Pharmacotherapy 1998; 18 (2): 392-8
248. Johns LE, Houlston RS. N-acetyl transferase-2 and bladder cancer risk: a meta-analysis. Environ Mol Mutagen 2000; 36 (3): 221-7
249. Green J, Banks E, Berrington A, et al. N-acetyltransferase 2 and bladder cancer: an overview and consideration of the evidence for gene-environment interaction. Br J Cancer 2000; 83 (3): 412-7
250. Spielberg SP. N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Pharmacokinet Biopharm 1996; 24 (5): 509-19
251. Hughes HB, BiehI JP, Jones A, et al. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberc 1954; 70 (2): 266-73
252. Lee W, Lockhart AC, Kim RB, et al. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug dezymes: velopment. Oncologist 2005; 10 (2): 104-11
253. Al Hadithy AF, de Boer NK, Derijks LJ, et al. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis 2005; 37 (4): 282-97
254. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126 (8): 608-14
255. Collie-Duguid ES, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999; 9 (1): 37-42
256. McLeod HL, Krynetski EY, Relling MV, et al. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000; 14 (4): 567-72
257. Schutz E, Gummert J, Mohr F, et al. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993; 341 (8842): 436
258. Coulthard SA, Matheson EC, Hall AG, et al. The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment. Nucleosides Nucleotides Nucleic Acids 2004; 23 (8-9): 1385-91
259. Evans WE. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit 2004; 26 (2): 186-91
260. Krynetski E, Evans WE. Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene 2003; 22 (47): 7403-13
261. Spector R. Drug transport in the mammalian central nervous system: multiple complex systems: a critical analysis and commentary. Pharmacology 2000; 60 (2): 58-73
262. Doherty MM, Charman WN. The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin Pharmacokinet 2002; 41 (4): 235-53
263. Uhr M, Steckler T, Yassouridis A, et al. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 2000; 22 (4): 380-7
264. Roberts RL, Joyce PR, Mulder RT, et al. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J 2002; 2 (3): 191-6
265. Sun J, He ZG, Cheng G, et al. Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit 2004; 10 (1): RA5-14
266. DuBuske LM. The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions. Drug Saf 2005; 28 (9): 789-801
267. Brinkmann U, Eichelbaum M. Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics J 2001; 1 (1): 59-64
268. Brinkmann U, Roots I, Eichelbaum M. Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Discov Today 2001; 6 (16): 835-9
269. Kerb R, Hoffmeyer S, Brinkmann U. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2001; 2 (1): 51-64
270. Sakaeda T, Nakamura T, Okumura K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull 2002; 25 (11): 1391-400
271. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97 (7): 3473-8
272. Sadeque AJ, Wandel C, He H, et al. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000; 68 (3): 231-7
273. Perry PJ, Pfohl BM, Holstad SG. The relationship between antidepressant response and tricyclic antidepressant plasma concentrations: a retrospective analysis of the literature using logistic regression analysis. Clin Pharmacokinet 1987; 13 (6): 381-92
274. Perry PJ, Zeilmann C, Arndt S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 1994; 14 (4): 230-40
275. Ulrich S, Neuhof S, Braun V, et al. Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder. Pharmacopsychiatry 1998; 31 (5): 163-9
276. Ulrich S, Lauter J. Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression. Clin Pharmacokinet 2002; 41 (11): 853-76
277. Ulrich S, Wurthmann C, Brosz M, et al. The relationship between serum concentration and therapeutic effect of haloper-idol in patients with acute schizophrenia. Clin Pharmacokinet 1998; 34 (3): 227-63
278. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Clomipramine concentration as a predictor of delayed response: a naturalistic study. Eur J Clin Pharmacol 1999; 54 (12): 895-902
279. Eilers R. Therapeutic drug monitoring for the treatment of psychiatric disorders: clinical use and cost effectiveness. Clin Pharmacokinet 1995; 29 (6): 442-50
280. Balant-Gorgia AE, Gex-Fabry M, Balant LP. Clinical pharmacokinetics of clomipramine. Clin Pharmacokinet 1991; 20 (6): 447-62
281. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988; 45 (1): 79-91
282. Rao ML, Hiemke C, Grasmäder K, et al. [Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring]. Fortschr Neurol Psychiatr 2001; 69 (11): 510-7
283. Hiemke C, Dragicevic A, Gründer G. Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 2004; 26 (2): 156-60
284. Asberg M, Sjoqvist F. On the role of plasma level monitoring of tricyclic antidepressants in clinical practice. Commun Psychopharmacol 1978; 2 (5): 381-91
285. de Oliveira IR, Dardennes RM, Amorim ES, et al. Is there a relationship between antipsychotic blood levels and their clinical efficacy? An analysis of studies design and methodology. Fundam Clin Pharmacol 1995; 9 (5): 488-502
286. Gram LF. Plasma level monitoring of tricyclic antidepressants: methodological and pharmacokinetic considerations. Commun Psychopharmacol 1978; 2 (5): 373-80
287. Preskorn SH, Burke MJ, Fast GA. Therapeutic drug monitoring: principles and practice. Psychiatr Clin North Am 1993; 16 (3): 611-45
288. Van Putten T, Marder SR. Variable dose studies provide misleading therapeutic windows. J Clin Psychopharmacol 1986; 6 (4): 249-50
289. Task Force on the Use of Laboratory Tests in Psychiatry. Tricyclic antidepressants: blood level measurements and clinical outcome: an APA Task Force report. Am J Psychiatry 1985; 142 (2): 155-62
290. Nyberg S, Nordstrom AL, Halldin C, et al. Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man. Int Clin Psychopharmacol 1995; 10 Suppl. 3: 81-5
291. Sedvall G, Farde L, Hall H, et al. Utilization of radioligands in schizophrenia research. Clin Neurosci 1995; 3 (2): 112-21
292. Rasmussen BB, Brosen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit 2000; 22 (2): 143-54
293. Hammer WM, Brodiet BB. Application of isotope derivative technique to assay of secondary amines: estimation of desipramine by acetylation with H3-acetic anhydride. J Pharmacol Exp Ther 1967; 157 (3): 503-8
294. Asberg M, Cronholm B, Sjoqvist F, et al. Relationship between plasma level and therapeutic effect of nortriptyline. BMJ 1971; 3 (770): 331-4
295. Mitchell PB. Therapeutic drug monitoring of psychotropic medications. Br J Clin Pharmacol 2001; 52: 45S-54S
296. Bengtsson F. Therapeutic drug monitoring of psychotropic drugs. TDM "nouveau". Ther Drug Monit 2004; 26 (2): 145-51
297. Vuille F, Amey M, Baumann P. Use of plasma level monitoring of antidepressants in clinical practice: towards an analysis of clinical utility. Pharmacopsychiatry 1991; 24 (6): 190-5
298. Gefvert O, Eriksson B, Persson P, et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (risperdal consta) in patients with schizophrenia. Int J Neuropsychopharmacol 2005; 8 (1): 27-36
299. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62 (15): 2169-83
300. Heller S, Hiemke C, Stroba G, et al. Assessment of storage and transport stability of new antidepressant and antipsychotic drugs for a nationwide TDM service. Ther Drug Monit 2004; 26 (4): 459-61
301. Morris RG, Holt DW, Armstrong VW, et al. Analytic aspects of cyclosporine monitoring, on behalf of the IFCC/IATDMCT Joint Working Group. Ther Drug Monit 2004; 26 (2): 227-30
302. Jusko WJ, Thomson AW, Fung J, et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit 1995; 17 (6): 606-14
303. Shaw LM, Sollinger HW, Halloran P, et al. Mycophenolate mofetil: a report of the consensus panel. Ther Drug Monit 1995; 17 (6): 690-9
304. Yatscoff RW, Boeckx R, Holt DW, et al. Consensus guidelines for therapeutic drug monitoring of rapamycin: report of the consensus panel. Ther Drug Monit 1995; 17 (6): 676-80
305. Kappelhoff BS, Crommentuyn KM, de Maat MM, et al. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet 2004; 43 (13): 845-53
306. Acosta EP, Gerber JG. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses 2002; 18 (12): 825-34
307. Peloquin CA. Tuberculosis drug serum levels. Clin Infect Dis 2001; 33 (4): 584-5
308. Regenthal R, Krueger M, Koeppel C, et al. Drug levels: therapeutic and toxic serum/plasma concentrations of common drugs. J Clin Monit Comput 1999; 15 (7-8): 529-44
309. Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 2003; 58 (7): 447-74
310. Ensom MH, Chang TK, Patel P. Pharmacogenetics: the therapeutic drug monitoring of the future? Clin Pharmacokinet 2001; 40 (11): 783-802
311. Chainuvati S, Nafziger AN, Leeder JS, et al. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase- 2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin Pharmacol Ther 2003; 74 (5): 437-47
312. Jerdi MC, Daali Y, Oestreicher MK, et al. A simplified analytical method for a phenotyping cocktail of major CYP450 biotransformation routes. J Pharm Biomed Anal 2004; 35 (5): 1203-12
313. Streetman DS, Bleakley JF, Kim JS, et al. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Coopers-town cocktail". Clin Pharmacol Ther 2000; 68 (4): 375-83
314. Dahl ML. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 2002; 41 (7): 453-70
315. Schubert L. Ethical implications of pharmacogenetics - do slippery slope arguments matter? Bioethics 2004; 18 (4): 361-78
316. Netzer C, Biller-Andorno N. Pharmacogenetic testing, informed consent and the problem of secondary information. Bioethics 2004; 18 (4): 344-60
317. Smart A, Martin P, Parker M. Tailored medicine: whom will it fit? The ethics of patient and disease stratification. Bioethics 2004; 18 (4): 322-42
318. van Delden J, Bolt I, Kalis A, et al. Tailor-made pharmacotherapy: future developments and ethical challenges in the field of pharmacogenomics. Bioethics 2004; 18 (4): 303-21
319. Paul NW, Roses AD. Pharmacogenetics and pharmacogenomics: recent developments, their clinical relevance and some ethical, social, and legal implications. J Mol Med 2003; 81 (3): 135-40
320. de Leon J, Barnhill J, Rogers T, et al. Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital. Am J Psychiatry 1998; 155 (9): 1278-80
321. Chou WH, Yan FX, de Leon J, et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 2000; 20 (2): 246-51
322. Rau T, Wohlleben G, Wuttke H, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther 2004; 75 (5): 386-93
323. Tamminga WJ, Wemer J, Oosterhuis B, et al. Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study. Eur J Clin Pharmacol 2003; 59 (1): 57-64
324. Mulder H, Wilmink FW, Beumer TL, et al. The association between cytochrome P450 2D6 genotype and prescription patterns of antipsychotic and antidepressant drugs in hospitalized psychiatric patients: a retrospective follow-up study. J Clin Psychopharmacol 2005; 25 (2): 188-91
325. de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66 (1): 15-27
326. Brockmöller J, Kirchheiner J, Schmider J, et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002; 72 (4): 438-52
327. de Leon J, Susce MT, Pan RM, et al. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol 2005; 25 (5): 448-56
328. Armstrong M, Daly AK, Blennerhassett R, et al. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry 1997; 170: 23-6
329. Reggiani K, Vandel P, Haffen E, et al. Effets indesirables extrapyramidaux des neuroleptiques et antidepresseurs: recherche de facteurs de risque: role du polymorphisme genetique du CYP2D6. L'Encephale 2000; 26 (1): 62-7
330. Steimer W, Zopf K, von Amelunxen S, et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem 2005; 51 (2): 376-85
331. Grasmäder K, Verwohlt PL, Rietschel M, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004; 60 (5): 329-36
332. Rau T, Heide R, Bergmann K, et al. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 2002; 12 (6): 465-72
333. Wuttke H, Rau T, Heide R, et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 2002; 72 (4): 429-37
334. Basile VS, Ozdemir V, Masellis M, et al. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 2000; 5 (4): 410-7
335. Tiwari AK, Deshpande SN, Rao AR, et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmacogenomics J 2005; 5 (1): 60-9
336. Lerer B, Segman RH, Fangerau H, et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002; 27 (1): 105-19
337. Ozdemir V, Basile VS, Masellis M, et al. Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes. J Biochem Biophys Methods 2001; 47 (1-2): 151-7
338. Taube J, Halsall D, Baglin T. Influence of cytochrome P450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96 (5): 1816-9
339. Wilke RA, Carrillo MW, Ritchie MD. Pacific symposium on biocomputing: computational approaches for pharmacogenomics. Pharmacogenomics 2005; 6 (2): 111-3
340. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005; 5 (1): 6-13
341. Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci 2000; 2 (3): E29
342. Simmons SA, Perry PJ, Rickert ED, et al. Cost-benefit analysis of prospective pharmacokinetic dosing of nortriptyline in depressed inpatients. J Affect Disord 1985; 8 (1): 47-53
343. Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry 1991; 52 Suppl.: 23-33
344. Lundmark J, Bengtsson F, Nordin C, et al. Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand 2000; 101 (5): 354-9
345. Muller MJ, Dragicevic A, Fric M, et al. Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions? Pharmacopsychiatry 2003; 36 (3): 98-104
346. Chen S, Chou WH, Blouin RA, et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996; 60 (5): 522-34
347. Frueh FW, Gurwitz D. From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics 2004; 5 (5): 571-9
348. Hug H, Bagatto D, Dannecker R, et al. ADRIS: the adverse drug reactions information scheme. Pharmacogenetics 2003; 13 (12): 767-72